STOCK TITAN

Biomarin Pharmaceutical Inc. - BMRN STOCK NEWS

Welcome to our dedicated news page for Biomarin Pharmaceutical (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biomarin Pharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biomarin Pharmaceutical's position in the market.

Rhea-AI Summary
BioMarin Pharmaceutical Inc. announces positive results from an investigator-sponsored Phase 2 study of VOXZOGO in children with hypochondroplasia and achondroplasia, showcasing significant growth improvements and quality of life enhancements. The company also highlights the long-term efficacy and safety of VOXZOGO in children with achondroplasia, with promising data presented at the 2024 ACMG Annual Clinical Genetics Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. appoints Cristin Hubbard as executive vice president and chief commercial officer, bringing over 20 years of experience in the biopharmaceutical and diagnostics industries. Hubbard will lead global commercial operations from May 20, succeeding Jeff Ajer. Hubbard's background includes roles at Roche Pharma and Roche Diagnostics, demonstrating expertise in lifecycle management, growth strategies, and leadership in various therapeutic areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
management
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (BMRN) announced participation in four investor conferences in March, with Brian Mueller, CFO, scheduled for fireside chats and 1x1 meetings. The conferences include Cowen 44th Annual Healthcare Conference, Leerink Partners Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and Barclays 26th Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
Rhea-AI Summary
BioMarin Pharmaceutical Inc. reports strong financial results for FY'23 with total revenues of $2.42 billion, a 15% YoY increase, and GAAP diluted earnings per share of $0.87 (+16% YoY). VOXZOGO® net revenues surged to $146 million in Q4'23 (+118% Q/Q) and $470 million for FY'23 (+178% YoY). The 2024 financial outlook anticipates double-digit total revenue growth and significant non-GAAP operating margin expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
earnings
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (BMRN) will host a conference call and webcast on February 22, 2024, to discuss the financial results and provide a general business update for the fourth quarter and full-year 2023. Interested parties can access the live audio webcast via the investor section of the BioMarin website. The call will be archived on the site for one week following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences earnings
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. announced new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) to be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress. Results from a Phase 2 study showed that median factor VIII (FVIII) activity at year seven remained in the mild hemophilia range and mean annualized bleeding rate (ABR) for treated bleeds over the full follow-up period decreased by 96% from baseline for adults with severe hemophilia A in the 6x1013 vg/kg dose cohort. Additional studies will be shared, including preliminary results from GENEr8-INH, a Phase 1/2 study evaluating the safety and efficacy of ROCTAVIAN in participants with active and prior FVIII inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that Alexander Hardy, President and CEO, will present at the 42nd Annual J.P. Morgan Conference on January 8, 2024. The presentation will be available via live audio webcast and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the appointment of three new independent directors, the establishment of a Strategic and Operating Review Committee, and cooperation and information sharing agreements with Elliott, to enhance corporate governance and long-term shareholder value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (BMRN) announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox), the first gene therapy for hemophilia to receive an approved federal price in Germany. The gross price of €28,933.53 per vial equates to approximately $900,000 per patient in net revenue to BioMarin, facilitating access to ROCTAVIAN for eligible individuals among the roughly 2,000 adults with severe hemophilia A in Germany. The agreement includes an outcome-based prospective cohort model for future reimbursement and ensures supply and reimbursement for eligible patients in Germany for a minimum term of 3 years. Final price negotiations with the Italian Medicines Agency are underway, and significant progress has been made with U.S. payers to increase access to treatment for approximately 2,500 eligible adults living with severe hemophilia A in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
Rhea-AI Summary
BioMarin Pharmaceutical Inc. announces narrowed financial guidance for full-year 2023. VOXZOGO approved for children without age restrictions in the US and for children aged 4 months and older in Europe. ROCTAVIAN reimbursement network on-track for global patient access. Full-year 2024 revenue expected to approach $3 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
earnings
Biomarin Pharmaceutical Inc.

Nasdaq:BMRN

BMRN Rankings

BMRN Stock Data

16.72B
187.26M
0.68%
101.51%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Novato

About BMRN

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment